In what CEO Dinesh Patel called a “front-end-loaded deal that is significant from now through successful completion of phase II trials,” Protagonist Therapeutics Inc. sealed a deal potentially worth $990 million with Janssen Biotech Inc., one of the Janssen Pharmaceutical companies of New Brunswick, N.J.-based Johnson & Johnson (J&J), for the co-development and commercialization of PTG-200.